influenza — grants · GrantIndex

Sort

21,281 grants matching “influenza”

Surveillance and Response to Avian and Pandemic Influenza by Regional Offices....

$1,332,000

Adamou A. Yada · World Health Organization--Afro · U51 · FY2006 · CI

Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses

$1,330,999

Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

Peptide inhbitors of influenza entry-FAST TRACK

$1,328,888

Russell B Wilson · Autoimmune Technologies, Llc · R44 · FY2011 · AI

Using parenteral combination adjuvants to induce pan-mucosal cellular and humoral immunity

$1,326,308

James B McLachlan · Tulane University Of Louisiana · R01 · FY2025 · AI

Does repeated influenza vaccination constrain influenza immune responses and protection?

$1,325,203

Sheena G Sullivan · University Of Melbourne · R01 · FY2022 · AI

VACCINE AND TREATMENT EVALUATION UNITS: PHASE I INFLUENZA VACCINE CLINICAL TRIAL

$1,322,957

Karen Kotloff · University Of Maryland Baltimore · N01 · FY2016 · AI

Capsule conjugate vaccines against Campylobacter jejuni

$1,322,611

Patricia Guerry · Henry M. Jackson Fdn For The Adv Mil/Med · U01 · FY2010 · AI

Harnessing Human DC Subsets for Improved Muscosal Vaccines

$1,322,064

Jacques F Banchereau · Baylor Research Institute · U19 · FY2010 · AI

VACCINE AND TREATMENT EVALUATION UNITS (VTEU)

$1,322,033

Wendy Keitel · Baylor College Of Medicine · N01 · FY2018 · AI

Immunology of Acute and Chronic Viral Hepatitis

$1,322,022

Barbara Rehermann · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2020 · DK

Monitoring of disease-induced skin VOC patterns from handheld and wearable chemical sensors

$1,320,252

Cristina Elizabeth Davis · University Of California At Davis · U01 · FY2024 · TR

CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH EFFORTS

$1,319,131

Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · N01 · FY2020 · AI

NIAID Centers of Excellence for Influenza Research and Response

$1,314,244

S. Mark Tompkins · University Of Georgia · N01 · FY2024 · AI

Screening Core

$1,313,870

James Robert Bostwick · University Of Alabama At Birmingham · U19 · FY2015 · AI

CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy

$1,313,567

Arthur P Bertolino · Cytoagents, Inc. · R44 · FY2025 · CA

Safety and Immunogenicity of H3N2 M2SR monovalent influenza vaccine in older subjects

$1,311,111

Pamuk Bilsel · Flugen, Inc. · U01 · FY2020 · AI

Probiotics to Enhance Influenza Vaccine Immunogenicity

$1,310,980

Patricia L Hibberd · Massachusetts General Hospital · U01 · FY2010 · AT

RFA-IP-22-004, Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027

$1,310,713

Karen J Wernli · Kaiser Foundation Health Plan Of Washington · U01 · FY2025 · IP

RFA-IP-22-004, Component A _ Credible Effectiveness Measures of Seasonal Influenza, COVID-19 and Other Respiratory Virus Vaccines against Ambulatory Care for Acute Illness in Texas (and Component D).

$1,310,713

Manjusha Gaglani · Baylor Research Institute · U01 · FY2025 · IP

RFA-IP-22-004:Michigan-Ford Initiative to Measure Vaccine Effectiveness (MFIVE): Seasonal Influenza, COVID-19 and Respiratory Virus Vaccines

$1,310,713

Emily Toth Martin · University Of Michigan At Ann Arbor · U01 · FY2025 · IP

IP21-002 Enhanced Surveillance for New Vaccine Preventable Diseases

$1,310,557

Natasha Bassam Halasa · Vanderbilt University Medical Center · U01 · FY2025 · IP

ADDRESSING EMERGING INFECTIOUS DISEASES IN BANGLADESH

$1,310,000

Leanne Elizabeth Unicomb · International Ctr/Diarrhoeal Dis Res · U01 · FY2011 · CI

Protein-mediated membrane remodeling

Advancing a Novel Pangenotypic Inhibitor of Human Influenza Virus to an IND

Influenza Viral Pathogenesis

Surveillance and Response to Avian and Pandemic Influenza by Regional Offices....

Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses

Peptide inhbitors of influenza entry-FAST TRACK

Using parenteral combination adjuvants to induce pan-mucosal cellular and humoral immunity

Does repeated influenza vaccination constrain influenza immune responses and protection?

VACCINE AND TREATMENT EVALUATION UNITS: PHASE I INFLUENZA VACCINE CLINICAL TRIAL

Capsule conjugate vaccines against Campylobacter jejuni

Harnessing Human DC Subsets for Improved Muscosal Vaccines

VACCINE AND TREATMENT EVALUATION UNITS (VTEU)

Immunology of Acute and Chronic Viral Hepatitis

Monitoring of disease-induced skin VOC patterns from handheld and wearable chemical sensors

CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH EFFORTS

NIAID Centers of Excellence for Influenza Research and Response

Screening Core

CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy

Safety and Immunogenicity of H3N2 M2SR monovalent influenza vaccine in older subjects

Probiotics to Enhance Influenza Vaccine Immunogenicity

RFA-IP-22-004, Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027

RFA-IP-22-004, Component A _ Credible Effectiveness Measures of Seasonal Influenza, COVID-19 and Other Respiratory Virus Vaccines against Ambulatory Care for Acute Illness in Texas (and Component D).

RFA-IP-22-004:Michigan-Ford Initiative to Measure Vaccine Effectiveness (MFIVE): Seasonal Influenza, COVID-19 and Respiratory Virus Vaccines

IP21-002 Enhanced Surveillance for New Vaccine Preventable Diseases

ADDRESSING EMERGING INFECTIOUS DISEASES IN BANGLADESH